Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review.

Campochiaro, Corrado; Lazzaroni, Maria Grazia; Bruni, Cosimo; Zanatta, Elisabetta; De Luca, Giacomo; Matucci-Cerinic, Marco

Campochiaro, Corrado; Lazzaroni, Maria Grazia; Bruni, Cosimo; Zanatta, Elisabetta; De Luca, Giacomo; Matucci-Cerinic, Marco.

Afiliación

Campochiaro C; Unit of Immunology, Rheumatology, Allergy and Rare Disease, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy. Via Olgettina 60, 20132, Milan, Italy.
Lazzaroni MG; Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia, Brescia, Italy.
Bruni C; Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Zanatta E; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
De Luca G; Department of Geriatric Medicine, Division of Rheumatology AOUC, Florence, Italy.
Matucci-Cerinic M; Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Ther Adv Musculoskelet Dis ; 14: 1759720X221116408, 2022.

Article en En | MEDLINE | ID: mdl-36051631

Palabras clave

abatacept; combination therapy; efficacy; interstitial lung disease; nintedanib; rituximab; safety; systemic sclerosis; tocilizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies / Systematic_reviews Idioma: En Revista: Ther Adv Musculoskelet Dis Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google